Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer By Ogkologos - July 15, 2025 756 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR EMA Adopts a New Pharmaceutical Form of Selumetinib December 16, 2025 Low-Dose Adjuvant Aspirin Decreases Incidence of Recurrence Among Patients with Resected... September 30, 2025 COVID-19 Vaccines Are Safe for People Receiving Cancer Immunotherapy, Study Confirms November 15, 2022 细针穿刺活检：如何准备和会发生什么 March 8, 2023 Load more HOT NEWS Opinion: ‘We’re speaking with One Cancer Voice, but is anyone listening?’ Michelle Mitchell: Cancer is a fixable problem Alabama’s Ventilator Rationing Plan Discriminates Against Disabled & Ill Patients, Advocacy... Man Born Without Legs Proves He’s Greater Than Any Obstacle He’s...
